Newsroom
Saniona Icon blue
Latest News
January 5, 2022
PRESS RELEASE January 5 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that it will present at multiple upcoming virtual investor conferences. Details are as follows: LifeSci Partners 11th Annual Corporate Access Event (Panel
December 28, 2021
PRESS RELEASE December 2 8 , 2021 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS). Tesomet is an investigational fixed-dose combination
December 2, 2021
PRESS RELEASE December 2 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the Chairman and the CEO, as well as additional members of the Board of Directors and executive management team, have purchased 82,000 shares of the
If you have any questions regarding Saniona's media communication, feel free to contact us at any time.
trista morrison
Trista Morrison, Chief Communications Officer Phone: +1 781.810.9227 Email: trista.morrison@saniona.com